If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This
newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Simple flat-rate database subscription plans
|
Drug Patent Expirations for Jun 18 2012Tradename | Applicant | Generic Name | Patent Number | Patent Expiration |
---|
EPZICOM | Viiv Hlthcare | abacavir sulfate; lamivudine | 5,034,394*PED | Jun 18, 2012 | TRIZIVIR | Viiv Hlthcare | abacavir sulfate; lamivudine; zidovudine | 5,034,394*PED | Jun 18, 2012 | ZIAGEN | Viiv Hlthcare | abacavir sulfate | 5,034,394*PED | Jun 18, 2012 | *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. |
DrugPatentWatch Serves Your Competitive Intelligence NeedsSubscribers have access to valuable datasets, including: - Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Sales data (top 200 drugs)
- Paragraph IV challenges
- Tentative approvals
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.